Indexed in

External link External link

License and use

Citations

Altmetrics

Analysis of institutional authors

Usandizaga Elio, RamonAuthorFrías Iniesta, JesúsAuthor

Share

Study on the conditions of use for Caribán® and other antiemetics in the treatment of nausea and vomiting during pregnancy

Publicated to:Progresos en Obstetricia y Ginecologia. 61 (5): 449,457-455 - 2018-09-01 61(5), DOI: 10.20960/j.pog.00130

Authors: Usandizaga Elio, Ramón; Meler Barrabés, Eva; Frías, L; Serrano Olmedo, Ariana; Martínez Ávila, José Carlos; Frías Iniesta, Jesús

Affiliations

Abstract

© 2018, Sociedad Espanola de Ginecologia y Obstetricia. All rights reserved. Objective: We performed a prospective observational study on the conditions of use of a medication, Caribán®, and of other antiemetics for the treatment of nausea and vomiting in pregnancy. The study was practical in design, and its main objective was to determine the frequency of use of Caribán® in the treatment of nausea and vomiting in pregnancy by analyzing conditions of use in daily clinical practice. Material and methods: The study population comprised 184 pregnant women with nausea and/or vomiting during the days preceding the first study visit. The patients attended up to 4 visits, 3 of which were face-to-face, and provided clinical follow-up data and data on the treatment used by means of an app. Data on treatment and the evaluation of nausea and vomiting were obtained every 24 hours using the Pregnancy-Unique Quantification of Emesis and Nausea score. Results: The most frequently used initial regimen was 1 capsule every 8 hours. Data were available from the baseline visit and from the daily follow-up of 158 women (ie, 4,982 daily evaluations). The mean score for severity of nausea and vomiting in pregnancy was 5.69 points (mild) (SD, 1.8; range, 3-13) and the mean cumulative dose per woman throughout the follow-up was 34.61 capsules (6-197). Nausea and vomiting in pregnancy was mild in 72.48% of evaluations, moderate in 26.57%, and severe in 0.94%. Patients did not take medication in 54% (n=1969) of the mild daily episodes and in 14% of the moderate episodes. Mean consumption per daily episode was 1.74 (0-10) capsules per episode of mild nausea and vomiting in pregnancy and 2.14 (0-35) capsules per episode of moderate nausea and vomiting in pregnancy. Women who had nausea and vomiting in pregnancy took Caribán® according to the app on 66.7% of the days with symptoms. Conclusions: The most common initial regimen prescribed was 1 capsule every 8 hours. Most of the episodes of nausea and vomiting in pregnancy were mild, and on 50.85% of days with mild nausea and vomiting in pregnancy, the women did not take medication. The mean daily dose per mild episode was 1.74 capsules. The patients reported having taken medication for moderate nausea and vomiting in pregnancy in 86% of cases. The mean dose per episode was 2.14 capsules. The patients took Caribán® on 66.7% of days with nausea and vomiting in pregnancy.

Keywords